| Robert Isaak, DO | |
|
Department Of Anesthesiology N2198 Unc, Cb# 7010, Chapel Hill, NC 27599-7010 | |
| (919) 966-5136 | |
| (984) 974-4873 |
| Full Name | Robert Isaak |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 17 Years |
| Location | Department Of Anesthesiology N2198 Unc, Chapel Hill, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104020692 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 2011-00659 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of North Carolina Hospital | Chapel hill, NC | Hospital |
| Wayne Memorial Hospital | Goldsboro, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Unc Physicians And Associates | 0648181156 | 1656 |
News Archive
Women 40 years and younger with early-stage breast cancer who receive an additional high dose of radiation (boost dose) after undergoing breast-conserving surgery (lumpectomy) and standard radiation treatment are almost twice as likely to be free of cancer 10 years after treatment compared to those who don't receive the boost dose, according to a large European study presented at the Plenary I session on October 29, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.
A new study found that opioid prescription use is more common in cancer survivors than in individuals without a history of cancer.
Vascular Cures, a leading non-profit investing in research to develop breakthrough treatments for vascular disease, announced results that indicate there may be a genetic basis for the varying outcomes of bypass surgery in the legs.
The Lancet Infectious Diseases recently published the results of an observational study led by researchers on Children's Hospital Colorado Infectious Disease and Neurology teams, along with counterparts at the Centers for Disease Control and Colorado Department of Public Health and Environment.
Threshold Pharmaceuticals, Inc., today announced two preclinical presentations on its clinical stage hypoxia-activated prodrug, TH-302, at the American Association for Cancer Research Translational Cancer Medicine Meeting, being held July 11 to 14, 2010, in San Francisco, CA. The preclinical presentations describe new findings regarding the efficacy of TH-302 when combined with multi-kinase inhibitors that inhibit VEGF signaling, as well as the efficacy of TH-302 in combination with gemcitabine in models of pancreatic cancer.
› Verified 2 days ago
| Entity Name | University Of North Carolina At Chapel Hill |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780669200 PECOS PAC ID: 0648181156 Enrollment ID: O20031105000359 |
News Archive
Women 40 years and younger with early-stage breast cancer who receive an additional high dose of radiation (boost dose) after undergoing breast-conserving surgery (lumpectomy) and standard radiation treatment are almost twice as likely to be free of cancer 10 years after treatment compared to those who don't receive the boost dose, according to a large European study presented at the Plenary I session on October 29, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.
A new study found that opioid prescription use is more common in cancer survivors than in individuals without a history of cancer.
Vascular Cures, a leading non-profit investing in research to develop breakthrough treatments for vascular disease, announced results that indicate there may be a genetic basis for the varying outcomes of bypass surgery in the legs.
The Lancet Infectious Diseases recently published the results of an observational study led by researchers on Children's Hospital Colorado Infectious Disease and Neurology teams, along with counterparts at the Centers for Disease Control and Colorado Department of Public Health and Environment.
Threshold Pharmaceuticals, Inc., today announced two preclinical presentations on its clinical stage hypoxia-activated prodrug, TH-302, at the American Association for Cancer Research Translational Cancer Medicine Meeting, being held July 11 to 14, 2010, in San Francisco, CA. The preclinical presentations describe new findings regarding the efficacy of TH-302 when combined with multi-kinase inhibitors that inhibit VEGF signaling, as well as the efficacy of TH-302 in combination with gemcitabine in models of pancreatic cancer.
› Verified 2 days ago
| Entity Name | Chatham Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689967457 PECOS PAC ID: 4284807868 Enrollment ID: O20111026000545 |
News Archive
Women 40 years and younger with early-stage breast cancer who receive an additional high dose of radiation (boost dose) after undergoing breast-conserving surgery (lumpectomy) and standard radiation treatment are almost twice as likely to be free of cancer 10 years after treatment compared to those who don't receive the boost dose, according to a large European study presented at the Plenary I session on October 29, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.
A new study found that opioid prescription use is more common in cancer survivors than in individuals without a history of cancer.
Vascular Cures, a leading non-profit investing in research to develop breakthrough treatments for vascular disease, announced results that indicate there may be a genetic basis for the varying outcomes of bypass surgery in the legs.
The Lancet Infectious Diseases recently published the results of an observational study led by researchers on Children's Hospital Colorado Infectious Disease and Neurology teams, along with counterparts at the Centers for Disease Control and Colorado Department of Public Health and Environment.
Threshold Pharmaceuticals, Inc., today announced two preclinical presentations on its clinical stage hypoxia-activated prodrug, TH-302, at the American Association for Cancer Research Translational Cancer Medicine Meeting, being held July 11 to 14, 2010, in San Francisco, CA. The preclinical presentations describe new findings regarding the efficacy of TH-302 when combined with multi-kinase inhibitors that inhibit VEGF signaling, as well as the efficacy of TH-302 in combination with gemcitabine in models of pancreatic cancer.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robert Isaak, DO Po Box 271647, Unc Fp, Salt Lake City, UT 84127-1647 Ph: (919) 966-8596 | Robert Isaak, DO Department Of Anesthesiology N2198 Unc, Cb# 7010, Chapel Hill, NC 27599-7010 Ph: (919) 966-5136 |
News Archive
Women 40 years and younger with early-stage breast cancer who receive an additional high dose of radiation (boost dose) after undergoing breast-conserving surgery (lumpectomy) and standard radiation treatment are almost twice as likely to be free of cancer 10 years after treatment compared to those who don't receive the boost dose, according to a large European study presented at the Plenary I session on October 29, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.
A new study found that opioid prescription use is more common in cancer survivors than in individuals without a history of cancer.
Vascular Cures, a leading non-profit investing in research to develop breakthrough treatments for vascular disease, announced results that indicate there may be a genetic basis for the varying outcomes of bypass surgery in the legs.
The Lancet Infectious Diseases recently published the results of an observational study led by researchers on Children's Hospital Colorado Infectious Disease and Neurology teams, along with counterparts at the Centers for Disease Control and Colorado Department of Public Health and Environment.
Threshold Pharmaceuticals, Inc., today announced two preclinical presentations on its clinical stage hypoxia-activated prodrug, TH-302, at the American Association for Cancer Research Translational Cancer Medicine Meeting, being held July 11 to 14, 2010, in San Francisco, CA. The preclinical presentations describe new findings regarding the efficacy of TH-302 when combined with multi-kinase inhibitors that inhibit VEGF signaling, as well as the efficacy of TH-302 in combination with gemcitabine in models of pancreatic cancer.
› Verified 2 days ago
Dr. Brian P Barrick, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: N2198 Unc Hospitals Clb # 7010, Department Of Anesthesiology, Chapel Hill, NC 27599 Phone: 919-966-5136 Fax: 984-971-4873 | |
Priya Kumar, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: N2198 Unc Hospitals Cb 7010, Department Of Anesthesiology, Chapel Hill, NC 27599 Phone: 919-966-5136 Fax: 984-974-4873 | |
Dr. David C Mayer, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 101 Manning Dr, Chapel Hill, NC 27599 Phone: 919-966-8596 Fax: 919-843-5515 | |
Kathryn Watson Cobb, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 101 Manning Dr, Room 1107g West Wing, Chapel Hill, NC 27514 Phone: 919-966-1072 Fax: 919-966-0290 | |
Dr. Jeremy D Deer, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 101 Manning Dr, Chapel Hill, NC 27514 Phone: 984-974-1000 | |
Jeremy Armbruster, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 101 Manning Dr, Chapel Hill, NC 27514 Phone: 984-974-1000 | |
Dr. Paul M Collins Jr., D.O. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 101 Manning Dr, Cb#7010, N2201 Unc Hospitals, Chapel Hill, NC 27599 Phone: 919-966-8596 Fax: 919-843-5515 |